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Abstract
Chronically elevated levels of fatty acids-FA can cause beta cell death in vitro. Beta cells vary in their individual susceptibility
to FA-toxicity. Rat beta cells were previously shown to better resist FA-toxicity in conditions that increased triglyceride
formation or mitochondrial and peroxisomal FA-oxidation, possibly reducing cytoplasmic levels of toxic FA-moieties. We
now show that stearoyl-CoA desaturase-SCD is involved in this cytoprotective mechanism through its ability to transfer
saturated FA into monounsaturated FA that are incorporated in lipids. In purified beta cells, SCD expression was induced by
LXR- and PPARa-agonists, which were found to protect rat, mouse and human beta cells against palmitate toxicity. When
their SCD was inhibited or silenced, the agonist-induced protection was also suppressed. A correlation between beta cell-
SCD expression and susceptibility to palmitate was also found in beta cell preparations isolated from different rodent
models. In mice with LXR-deletion (LXRb
-/- and LXRab
-/-), beta cells presented a reduced SCD-expression as well as an
increased susceptibility to palmitate-toxicity, which could not be counteracted by LXR or PPARa agonists. In Zucker fatty
rats and in rats treated with the LXR-agonist TO1317, beta cells show an increased SCD-expression and lower palmitate-
toxicity. In the normal rat beta cell population, the subpopulation with lower metabolic responsiveness to glucose exhibits a
lower SCD1 expression and a higher susceptibility to palmitate toxicity. These data demonstrate that the beta cell
susceptibility to saturated fatty acids can be reduced by stearoyl-coA desaturase, which upon stimulation by LXR and PPARa
agonists favors their desaturation and subsequent incorporation in neutral lipids.
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Introduction
Chronically elevated levels of saturated fatty acids may cause a
reduction in beta cell mass during the pathogenesis of type 2
diabetes. Supporting evidence comes primarily from animal
models and in vitro studies in which high fatty acid concentrations
induce beta cell dysfunction and death [1-4]. Depending on the
laboratory model, the lipotoxic process is seen (in)dependently of
glucotoxic influences [5]. In cultures of purified rat beta cells, we
found that palmitate was cytotoxic irrespective of the glucose
concentration but that the cells varied in their susceptibility, some
of them surviving while others rapidly or progressively proceeded
to necrosis or apoptosis [6,7]. This observation is another
illustration of the functional heterogeneity in the beta cell
population whereby cells differ in their individual sensitivities
and/or defense mechanisms [8-10]. Fatty acid (FA) toxicity was
found inversely related to the cellular ability to incorporate them
as neutral lipids in the cytoplasm [6]. The capacity to form
cytoplasmatic lipid droplets may thus serve as a cytoprotective
mechanism by preventing accumulation of toxic non-esterified FA
[6,11]. Unsaturated FA such as oleate can channel palmitate into
triglyceride pools away from pathways leading to cellular apoptosis
[12-14]. A second protective mechanism consists in increasing
breakdown of fatty acids in the beta cells [15,16]. We recently
demonstrated that the cytoprotective effect of PPARa agonists
against long-chain fatty acid toxicity is associated with increased
rates of b-oxidation and peroxisomal activity [7]. During the latter
study we noticed that PPARa agonists also induced a higher
expression of stearoyl CoA Desaturase (SCD), which is known to
generate monounsaturated FA from palmitate and thus facilitates
their incorporation into lipid reserves [17,18], instead of their
accumulation as non-esterified fatty acids or via an increased
PLoS ONE | www.plosone.org 1 September 2009 | Volume 4 | Issue 9 | e7266incorporation in ceramides [19]. Elevated SCD-levels have been
shown to protect against saturated fatty acids in a number of cell
types, including MIN6 cells [19-21]. The present study was
undertaken to investigate the potential contribution of SCD in the
detoxifying action of PPARa agonists.
Since the SCD1 and 2 enzymes are direct downstream targets of
Liver X Receptors (LXR) [22], we started by examining whether
LXR agonists can protect beta cells against palmitate through an
SCD-dependent mechanism. LXRa and LXRb are nuclear
oxysterol receptors with established roles in cholesterol, lipid,
and carbohydrate metabolism [23,24], and have recently been
shown to play an important role in maintaining beta cell function
[25,26].
Results
Activation of LXR protects beta cells against palmitate
toxicity
Rat beta cells were cultured with palmitate (C16:0) in presence
or absence of LXR agonists. Culture with 500 mM palmitate-2
days (500 mM-P) or 250 mM-8 days (250 mM-P) resulted in a
cytotoxicity of 29 and 38% respectively (Figure 1a). The LXR
agonists TO1317 and GW3965 protected against both conditions
keeping cell death below 10%. On the other hand, no protection
was seen with the FXR and PXR agonists GW4064 and
pregnenolone carbonitrile (PCN), which supports LXR specific
protection. TO1317 was also found to protect human beta cells
(Figure 1a). The protective effect of TO1317 was maintained over
16 days: 1062% dead cells at 250 mM-P with the agonist versus
5565% without (Figure 1b). Protection was also observed when
TO1317 was added 24 h after starting cultures with 250 mM-P:
1668% dead cells after 8 days versus 4065% in its absence
(P,0.01) (data not shown). None of the tested agonists influenced
beta cell survival in absence of palmitate.
Pre-treatment of beta cells with TO1317 also protected against
a subsequent exposure to 250 mM-P (Table 1). During a first
period of 8 days, beta cells were cultured with or without the
agonist; 250 mM-P was added on day 8 and culture continued
without agonist. Protection was sustained up to 8 days in cells
exposed to palmitate after removal of the protective agonist:
Figure 1. Agonists for LXR protect primary beta cells against palmitate toxicity. a) Rat and human beta cells were exposed to 500 mM-P, or
250 mM-P in the absence or presence of agonists for LXR (10 mM TO1317 or 1 mM GW3965), FXR (5 mM GW4064), or PXR (30 mM PCN). Data shown as
mean+sd, n=4-10, * p,0.05, ** p,0.01, *** p,0.001, versus palmitate b) Time course over 16 days for the toxicity of 250 mM-P6TO1317 (1 mM) in
rat beta cells. Data shown as mean+sd, n=7-10.
doi:10.1371/journal.pone.0007266.g001
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under control conditions for 8 days showed a comparable
cytotoxic response as freshly isolated cells when subsequently
exposed to palmitate for 2 to 8 days, indicating that prolonged
culture did not alter their susceptibility for palmitate.
In contrast to PPARa agonists that induce protection to
saturated and mono-unsaturated FA [7], TO1317 did not protect
against palmitoleate (C16:1), vaccenate (C18:1 n-7) or oleate
(C18:1 n-9), while it protected against stearate (C18:0) (Table S1).
Effect of LXR agonist on intracellular lipid accumulation
In electron microscopy, beta cells exposed to 250 mM-P
presented spindle-shaped empty-looking structures associated with
the endoplasmatic reticulum (Figure 2a), and that have previously
been associated with ER-stress and lipotoxicity [27,28]; We noticed
their presence in living cells, where their abundance seemed
increasedinthepresenceof TO1317.Asdemonstrated byMoffitt et
al. [28], these structures correspond to lipid droplets in living cells
when examined using light microscopy by vital nile-red staining;
their number was markedly increased in the TO1317 condition
(Figure 2a). These spindle structures and lipid droplets were not
found in control cells cultured with or without TO1317 alone.
Table 1. Effect of TO1317 pretreatment on palmitate toxicity.
Percent cytotoxicity
Pre-culture Final condition 2 days 8 days
Control C16:0 14623 8 63
TO1317 C16:0+TO1317 162
$ 1263
$
TO1317 C16:0 563
$ 2363
$
C16:0+TO1317 C16:0 462
$ 3266
Beta cells were pre-cultured for 8 days in absence or presence of 1 mM TO1317
or 250 mM-P; on day 8 these conditions were replaced by the final conditions, as
indicated, and the resulting cytotoxicities were measured after 2 or 8 days.
Mean6SD, n=4.
$p,0.001, versus control.
doi:10.1371/journal.pone.0007266.t001
Figure 2. Effect of LXR agonist on intracellular lipid accumulation and palmitate metabolism. a) Representative figure showing electron
microscopy and vital nile red staining on control cells, and beta cells exposed to 250 mM-P for 2 days6TO1317 (10 mM). Magnification: EM 2550x, Nile
red (green) + nuclear Hoechst (red) staining: 60x. b) Effect of 250 mM-P6TO1317 on
14C-palmitate metabolism. Beta-cells were cultured for 24 h in the
absence (white bars) or presence (gray bars) of 250 mM-P6TO1317, and subsequently incubated for 2 hrs with
14C-palmitic acid. Metabolism was
measured as recovery of
14C-label in CO2, in lipids and lipid intermediates (pmol/2 h/10
3 cells) and expressed as percentages of the control condition.
Data shown as mean6se (n=4), Student’s t-test,
$$ P,0.01 and
$$$ P,0.001, versus control; * P,0.05 and ** P,0.01 versus palmitate.
doi:10.1371/journal.pone.0007266.g002
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transfer palmitate into cellular lipids, by measuring the incorpo-
ration of
14C-palmitate-derived carbon over a period of 2 hrs in
cellular lipids, or as
14CO2-production, in control cells and in cells
pre-exposed for 24hrs to 250 mM-P. Presence of 1 mM TO1317
stimulated the
14C-flux into lipids by 50616% as compared to
control (p,0.01) (Figure 2b). In contrast to the recent study by
Green et al. [29], TO1317 was found to suppress
14C-palmitate
oxidation in both the palmitate and the control condition. The
apparent negative effect of 250 mM-P pre-exposure on
14CO2-
formation is explained by a dilution effect on the
14C-label due to
the increased intracellular palmitate levels, as shown before [7].
These observations support the view that channeling FA into
stored neutral lipids correlates with protection against the
cytotoxicity of cytoplasmic free acyl moieties and indicates the
involvement of LXR in this process.
Effect of LXR agonist on mRNA expression of
desaturation enzymes in beta cells
We examined the effect of TO1317 on mRNA expression of
enzymes involved in fatty acid elongation (ELOvl 5 and 6),
desaturation (SCD1 and 2) and esterification (DGAT1 and 2,
SOAT 1 and 2) (Figure 3a). Since PPARa agonists have been
previously found to induce beta cell protection through effects on
enzymes that regulate palmitate metabolism [7], we compared the
effects of the LXR agonist with those of the PPARa agonist
combination clofibrate plus 9cis RA (Table 2).
When beta cells are compared with liver, brain, white adipose
tissue (WAT) and endocrine alpha cells, they exhibit a high
expression of SCD2, FA elongase-5 (ELOvl5) and sterol-O-acyl
transferase-1(SOAT1), and a low expressionof SCD1, ELOvl6, and
the diacyl glycerol acyltransferase-1 and 2 (DGAT1 and DGAT2)
Figure 3. Enzymes involved in conversion of palmitate in response TO1317. a) Overview of enzymes involved in conversion of palmitate
(C16:0) to palmitoylate (C16:1), vaccinate (C18:1 n-7), stearate (C18:0) and oleate (C18:1 n-9): stearoyl CoA desaturase (SCD1, SCD2), elongases (ELOvl5,
ELOvl6), diacylglycerol transferase (DGAT1, DGAT2), sterol-O-acyl transferase (SOAT1, SOAT2). TG, triglycerides; CE, cholesteryl esters. b) qPCR result
examining the mRNA levels of the above enzymes in freshly isolated rat beta cells, alpha-cells and liver, white adipose and brain tissue. Gene
expression levels were normalized to actin, n=3. c) qPCR analysis for SCD1 and 2, showing the effect of 8 days 250 mM-P6TO1317. Data shown as
mean6sd, n=4, *** p,0.001, compared to control;
$ p,0.05,
$$$ p,0.001, versus TO1317. d) Representative immunoblot showing SCD protein
levels in beta cells cultured for 8 days with or without 250 mM-P6TO1317 (10 mM). Equal amounts of total protein were added on a 10%
polyacrylamide gel. Representative for 4 independent experiments.
doi:10.1371/journal.pone.0007266.g003
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of SCD1 and 2 by,respectively 50and30%(Table2);inpresence of
TO1317 these expressions were 5 and 3-fold higher than in its
absence; a stimulation was also seen with the PPARa agonist
combination (Table 2), but not observed in the presence of 9cis RA
alone (results not shown). The effect of TO1317 on mRNA
expression of SCD1 and SCD2 was accompanied by a similar effect
on their protein expression (Figures 3c, 3d). The presence of
250 mM-Pdid not significantly alterthe expression ofthe elongation
and esterification enzymes (Table 2). It was however found to
reduce the expression of the transcription factors PPARa and FXR,
an effect that was counteracted by the presence of an LXR or
PPARa agonist (Table 2). Both agonists also caused a marked
increase in the expression of SREBP1c, which is compatible with
the earlier reported role of SREBP1c in controlling SCD expression
downstream of PPARa and LXR [22].
In contrast to PPARa agonists, the LXR agonist did not
stimulate expression of enzymes involved in mitochondrial and
peroxisomal oxidation. On the contrary, inhibitions up to 40%
were measured (Table 2), which is compatible with the observed
suppression of
14C-palmitate oxidation (Figure 2b).
Inhibition of stearoyl-coenzyme A desaturase reverses
the cytoprotective effects of LXR and PPARa agonists in
beta cells
In view of their effects on expression of SCD1 and SCD2 we
examined whether the cytoprotective effects of the LXR and
PPARa agonists were influenced by t10,c12-conjugated linoleic
acid, a known inhibitor of SCD, or by its analog c9,t11-CLA,
which has no effect on SCD activity [20]. Rat beta cells were
cultured with 250 mM-P plus TO1317 for 8 days in the presence
or absence of one of these compounds. The SCD-active CLA
(t10,c12-CLA - 40 mM) not only prevented the protective effect of
TO1317 but also augmented palmitate cytotoxicity, while no
effect was seen with c9,t11-CLA (Figure 4a). This was also the case
for the clofibrate-retinoic acid combination. None of the CLA-
compounds were toxic by themselves, while they showed a mild
protective effect on palmitate toxicity in the absence of TO1317 in
rat beta cells. At this moment we can only speculate why both the
active and the inactive CLA-isomers provided protection to
palmitate in rat beta cells. t10,c12-CLA did not show this effect on
human cells where it was - as expected - found to increase
250 mM-P toxicity in the presence, as well as in the absence of
TO1317 (Figure 4a). Up to 5 different SCDs have been described
in mammals with their own specific FA-preferences, whereas the
effects of the CLAs have only been described for SCD1. It can thus
not be excluded that other SCDs could be influenced by CLA
treatment, and may affect palmitate toxicity. Our observations in
rat beta cells indicate that the action of t10,c12-CLA on palmitate
toxicity depends on the induction of SCD1 and SCD2 by
TO1317, whereas cell survival in the absence of TO1317 does not
depend on basal desaturase activity.
The SCD-active CLA (t10,c12 CLA) interfered with the effects
of TO1317 on palmitate conversion as illustrated by GC-MS
profiles of beta cells following culture. In the absence of palmitate
and TO1317, beta cells exhibited comparable levels of C16:0,
C18:0 (stearic acid) and arachidonic acid (C20:4), whereas their
Table 2. Effect of palmitate and LXR or PPARa agonists on gene mRNA expression levels calculated as DDCt values compared to
the indicated control conditions.
Genes C16:0 TO1317 C16:0+TO1317 C16:0+clof/9-cis RA
Compared to control Compared to control Compared to C16:0 Compared to C16:0
LXRa 1.460.3 2.561.3 * 1.360.7 1.760.6**
LXRb 0.860.3 1.460.5 1.060.3 1.060.4
PPARa 0.760.2* 1.160.6 1.360.4 1.960.4 ***
FXR 0.760.1 * 1.060.1 1.160.4 1.660.5 **
SREBP1c 0.860.2 3.360.7 *** 3.561.2 *** 2.860.5 **
SCD1 0.560.2 *** 2.260.3 *** 2.560.6 *** 5.862.7 ***
SCD2 0.760.1 *** 1.860.3 ** 2.460.3 *** 2.660.6 ***
ELOvl5 0.860.3 1.860.5 1.360.3 2.360.7 *
ELOvl6 0.860.1 1.960.6 ** 1.060.3 2.460.8 *
GPAT 1.160.3 1.260.5 1.260.1 1.560.2 **
DGAT1 1.060.1 1.660.4 0.760.3 0.960.2
DGAT2 1.760.6 1.960.7 ** 1.060.3 1.160.3
SOAT1 1.761.0 0.960.2 1.060.1 1.260.5
CPT1 1.960.6 ** 1.260.1 0.660.2 * 1.960.2 ***
Acad l 1.460.7 0.860.1 0.760.2 * 1.560.2 **
Acad m 0.860.2 1.160.2 1.060.1 1.660.3 **
Acaa2 1.360.4 1.560.3 0.660.3 * 1.660.1 ***
Acaa1 0.860.2 1.960.5 * 0.860.4 1.660.1 ***
Acox1 1.060.3 1.260.2 0.760.3 1.660.4 **
Acox3 1.460.9 1.460.4 0.860.3 1.560.2 ***
Beta cells were exposed for 2 days to 250 mM-P61 mM TO1317, or 250 mM clofibrate/2 mM 9-cis RA. qPCR values were normalized to actin and compared relative to the
respective control conditions. Unpaired student t-test, two tailed, mean6SD, n=4 – 6, * p,0.05, ** p,0.01, *** p,0.001.
doi:10.1371/journal.pone.0007266.t002
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lower, and those of C16:1 (palmitoleic acid) very low (Figure S1a).
Culture with 250 mM-P led to a marked increase of the C16:1
fraction, and lowered C18:0 and C18:1 (n-7 and n-9) levels
(Figure 4b). Consistent with a stimulatory effect on SCD, addition
of TO1317 was found to normalize the C18:1 n-7 levels, but did
not prevent the changes in C18:0, C18:1 n-9 and C16:1. The
SCD-active CLA counteracted the effect of TO1317 on C18:1 n-
7, and blocked formation of C16:1 and C18:1 n-9. No change was
seen for the levels of C20:4 (arachidonic acid), a fatty acid derived
from C18:2 (linoleic acid) through D5- and D6-desaturases, further
indicating specific involvement of the D9 desaturase pathway. We
noticed a higher C16:0 peak area after palmitate exposure, but it is
impossible to discriminate whether this reflects uptake or
adherence of the fatty acid. The effects of TO1317 and t10,c12
CLA on the ratios of saturated over monounsaturated fatty acids
are shown in Figure S1b.
The role of SCD in beta cell protection against palmitate was
further examined by RNA interference with this protein. Exposure
of beta cells for 48 h to 50 nM siRNA-cationic lipid complexes
targeted to both SCD1 and SCD2 resulted in a significant
decrease in SCD-RNA levels (by 7863% for SCD1, and 51612%
for SCD2 respectively), without affecting SREBP1c, LXR and
PPARa mRNA levels (not shown). Jetsi-ENDO control and
SiGLO risk free treated cells were used as control. Cell viability
was not affected by the transfection protocol, and siRNA knock-
down of SCD did not affect cell viability when compared to
controls. Under these conditions, cells were taken 24 h after
Figure 4. D9-desaturase activity plays a key role in protection against palmitate toxicity. a) Effect of inhibition of SCD. Rat and human
beta cells were exposed to 250 mM-P or 500 mM-P610 mM TO1317 or 250 mM clofibrate/2 mM 9RA, and/or c9,t11 CLA (40 mM), or t10,c12 CLA (40 mM).
Percentage cytotoxicity shown as mean+sd, n=3-4, *** p,0.001, versus palmitate. b) Effect of treatment on fatty acid composition as measured by
GC-MS. Beta cells were exposed to 250 mM-P610 mM TO1317 and640 nM t10,c12 CLA for 8 days. The levels for C16:0, C18:0, C16:1, C18:1 and C20:4
measured as nmol/nmol Pi were expressed relative to their levels in control cells (ratios of saturated over monounsaturated FA are shown in Figure
S1). Mean6sd, n=4 - 6, * p,0.05 versus control, $ p,0.05 versus palmitate. c) RNA interference. Beta cells were transfected with a pool of siRNA’s
directed against SCD1 and 2 (Si-SCD1/SCD2), and exposed to 250 mM-P and/or TO1317 for 3 days. Si-control cells were treated with lipid transfection
carrier (jetsi endo) only, or a pool of siGlo risk-free siRNA’s (siGlo). Percentage cytotoxicity shown as mean+sd, n=4, * p,0.05, *** p,0.001, versus Si-
control cells.
doi:10.1371/journal.pone.0007266.g004
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250 mM-P with or without TO1317 (10 mM) (Figure 4c). SCD1/
SCD2 siRNA-treated beta cells showed an increased palmitate
toxicity (4768%) as compared to control-transfected cells (Jetsi-
ENDO control and SiGLO risk-free treated cells, p,0.05, n=4)
(Figure 4c). Moreover, protection by TO1317 was lost in SCD1/
SCD2 siRNA-treated beta cells. Comparable results were obtained
when cells were transfected with siRNAs directed to either SCD1
or SCD2 (data not shown). Cell viability was not affected by the
transfection protocol, and siRNA knock-down of SCD did not
affect cell viability when compared to controls.
Interaction between desaturation pathway and palmitate
induced ER stress
A causal relation between palmitate toxicity, ER stress and the
accumulation of spindle-shaped structures in the ER has been
suggested [27,28,30]. In our experiments these structures accu-
mulated under protective conditions (See Figure 2). We therefore
studied the expression of ER-stress markers in response to
palmitate with, or without TO1317. Using this strategy we could,
however, not establish a clear correlation between ER-stress,
palmitate induced toxicity and protection against it (Table 3).
When rat beta cells were exposed to 500 mM-P for 2 days – a
condition with acute cell death- the expression levels of DNA-
damage inducible transcript 3 (Ddit3/Chop) were found in-
creased, in the absence, as well as in the presence of TO1317,
while those of DnaJ homologue C3 (DnaJc3/P58) and heat shock
70 kDa protein 5 (HSPA5) remained unaffected (Table 3). No
changes in expression for ER stress markers were found when cells
were exposed to 250 mM-P with or without TO1317. We
therefore further addressed this question by looking upstream
from SCD. D9-desaturation requires electrons supplied via
Ncb5or (NAD(P)H-cytochrome b5 oxidoreductase) [31]. Ncb5or
was recently found to protect cells against palmitate induced ER-
stress and lipotoxicity. Cells lacking Ncb5or
-/- show more signs of
ER stress and a higher cytotoxicity in response to palmitate [32].
We found the expression levels of Ncb5or induced by TO1317 in
presence of 250 mM and 500 mM-P, but not influenced by
palmitate on its own (Table 3). These observations are consistent
with a role of SCD to channel palmitate into less harmful
pathways such as accumulation into neutral lipids, and -in our
view- dissociate the accumulation of these lipids in the ER from
apoptosis, since more of these spindle-shaped structures were
formed under protective conditions.
LXR isotype specificity in modulation of palmitate toxicity
through SCD and SREBP1
The cytoprotective effects of LXR and PPARa agonists were
measured in beta cell preparations isolated from LXRa
-/-,
LXRb
-/-, LXRab
-/- and wild type mice. Beta cell survival in
control conditions was similar for the 4 genotypes and was not
influenced by the presence of TO1317 or clofibrate/9-cis RA.
Culture with 250 mM-P was cytotoxic for the four preparations
(Figure 5a). Beta cells from LXRb
-/- and LXRab
-/- mice showed a
much higher susceptibility to palmitate-toxicity (almost 100% cell
death) than wild type cells, whereas those from LXRa
-/- mice were
less susceptible. No differences in oleate toxicity were seen
(Figure 5a). The same observations were made when cells were
exposed to 100 mM-P, leading to almost 70% cell death in absence
of LXRb (results not shown). Beta cells from wild-type mice were
strongly protected by the LXR-agonist TO1317, as well as by
clofibrate/9-cis RA. This was not the case for LXRa
-/-, LXRb
-/-
and LXRab
-/- (Figure 5a). These observations indicate that the
protective action of PPARa agonists on palmitate toxicity depend
on the presence of both LXRa and b and downstream signaling
pathways.
We also conducted the above-described mRNA analysis on
islets isolated from LXRa
-/-, LXRb
-/-, LXRab
-/- and wild type
mice (Table S2). The islets did not present obvious differences in
cellular composition with more than 65% percent beta cells in
each preparation (results not shown). No significant differences
were noticed between islets from wild-type mice and from
LXRa
-/-mice, while absence of LXRb was associated with a
markedly reduced expression of SCD1 and 2, and of SREBP1c
(Figure 5b), and higher expression of DGAT1, SOAT1, and
ELOvl5 (Table S2). This observation is compatible with a key role
of LXRb in the expression of SCD and SREBP1c, and their
influence on the cellular susceptibility to palmitate toxicity and
further supports a role of SREBP1c downstream of LXR ,
PPARa [33].
Correlation between SCD expression in isolated beta cells
and their susceptibility to palmitate
The view that SCD-expression in beta cells may vary with their
environmental conditions in vivo, led us to explore three
conditions in which rat beta cells could be expected to express
higher SCD-levels after isolation. These preparations were then
analyzed for their susceptibility to palmitate toxicity.
The first condition is represented by beta cells isolated from Zucker
fatty rats lacking leptin receptor (fa/fa). Since leptin suppresses
SCD [34] these animals show increased D9-desaturation activities
and decreased saturated/mono-unsaturated fatty acid ratios in
serum and tissues, including pancreas [35]. Compare to their lean
controls (fa/-), beta cells from fa/fa animals showed 2-fold higher
mRNA levels for SCD1, SCD2; their LXRa expression was also
elevated, whereas PPARa expression was suppressed (Figure 6a),
Table S3. Beta cells isolated from fa/fa animals showed a
significantly lower susceptibility to palmitate-induced cell death
than those isolated from lean controls (fa/-): after 8 days the
cytotoxicity of 250 mM-P and 500 mM-P was, respectively, 662%
Table 3. Effect of palmitate and LXR agonists on genes related to ER-stress.
Genes TO1317 250 mM-P 250 mM-P+TO1317 500 mM-P 500 mM-P+TO1317
Ddit3 1.260.2 1.160.1 1.360.2 1.860.3 * 1.860.2 *
Dnajc3 0.760.1 * 1.060.2 0.760.02 * 0.860.2 0.860.1
Hsp5a 0.860.1 1.060.2 0.860.2 1.560.3 1.160.1
Ncb5OR 1.560.3 1.360.1 1.560.1 * 1.060.1 1.560.1 *
qPCR values normalized against actin and expressed relative to the control condition (vehicle treated). Cells were exposed for 2 days to 250 mM-P or 500 mM-P with or
without 10 mM TO1317. Student t-test, two tailed, mean6s d ,N=3–6 ,*p ,0.05, ** p,0.01.
doi:10.1371/journal.pone.0007266.t003
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controls (Figure 6b). In contrast, the cytotoxicity of oleate was low
and similar in both preparations. When the LXR-agonist TO1317
was added to the palmitate conditions, it gave a mild reduction of
palmitate toxicity in fa/fa beta cells, whereas fa/- cells were
efficiently protected. Protection was counteracted by the SCD
inhibitor t10,c12 CLA which even amplified the palmitate toxicity
in both cell preparations. Beta cell vitalities of cells isolated from
lean and Fatty Zucker rats were similar in control conditions.
These data indicate that differences in SCD expression and
activity in beta cells have consequences for their susceptibility to
saturated fatty acids.
The second condition was experimentally induced by treatment of
rats with the LXR agonist TO1317 (40 mg/kg body weight by oral
gavage for 5 days) or with a control vehicle. The pancreases were
then removed for purification of beta cells and alpha cell enriched
fractions by FACS-sorting. Beta cells from TO1317-treated rats
showed elevated SCD1, SCD2 and SREBP1c mRNA levels, and
similar levels of LXRa, LXRb and PPARa (Figure 6c). Their
palmitate susceptibility was lower after 500 mM-P -2 days but
could not be further reduced by addition of LXR or PPARa
agonists, while these compounds induced protection in the vehicle-
derived beta cells. Cells from TO1317-treated and vehicle-treated
animals showed the same low oleate cytotoxicity (Figure 6d).
Comparable data were obtained after culture at 250 mM-P for 8
days (cytotoxicity of 1063% in TO1317-cells versus 3061% in
vehicle-cells). These observations indicate that in vivo treatment
with the LXR-agonist has induced a beta cell phenotype with a
sustained protection against palmitate. In prior work we showed
that clof/9-cis RA did not influence palmitate toxicity in alpha-cell
enriched preparations [7]. In the present study alpha-cell enriched
preparations from TO1317- or vehicle-treated rats exhibited the
same palmitate toxicity; this was also the case when TO1317 was
added to the culture medium. No differences were seen in the
viability of the beta cell or alpha cell-enriched preparations
isolated from TO1317- or vehicle-treated rats and cultured in the
control condition
In prior work we have shown that primary beta cells can be less
susceptible or even resistant to palmitate toxicity, and that this
property is heterogeneously expressed [7]. To explore this
observation, and as a third condition, we have separated freshly
isolated rat beta cells into two subpopulations according to their
cellular metabolic responsiveness to an acute 7.5 mM glucose
stimulation, as described in prior studies by our group [8,36]. The
high-responsive beta cells were found to express higher levels of
SCD1 and LXRa than the low-responsive beta cells; their higher
expression of glucokinase was confirmed and served as an index
for their higher metabolic responsiveness (Figure 6e) [37]. They
also presented a lower cytotoxicity after 8 days culture with
250 mM-P (Figure 6f), or 2 days with 500 mM-P (data not shown).
Addition of the LXR- or PPARa-agonists exerted a much more
pronounced protective effect in the low-responsive subpopulation,
which is in part related to their higher palmitate toxicity but which
also indicates that they can generate cytoprotective mechanisms
when receiving extracellular signals. As with the previously
described conditions, the two tested cell populations underwent
a similar low oleate cytotoxicity.
Discussion
The mechanisms regulating the balance between functional
adaptation, lipid accumulation, dysfunction, or beta cell death in
response to chronic elevated FA levels are poorly understood.
Clarifying these mechanisms could help to develop new strategies
to prevent beta cell deterioration in type 2 diabetes. Several studies
have reported the potential of PPAR ligands to preserve functional
Figure 5. Effect of LXR and PPARa agonists on palmitate toxicity in LXR KO beta cells. Primary mouse beta cells were exposed to a)
250 mM-P or 250 mM oleate for 8 days in presence or absence of 1 mM TO1317 or 250 mM clofibrate/2 mM 9-cis RA. Percentages of cytotoxicity are
shown as mean+sd, n=3, *** p,0.001, TO1317 and clofibrate/9RA versus palmitate;
$$$ p,0.001, palmitate toxicity in LXR
-/- as versus wild type. b)
SCD1, SCD2 and SREBP1c mRNA levels in LXR
-/- islets as compared to wild type. Q-PCR signals shown as mean+sd, n=3, * p,0.001.
doi:10.1371/journal.pone.0007266.g005
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PLoS ONE | www.plosone.org 8 September 2009 | Volume 4 | Issue 9 | e7266Figure 6. SCD levels regulate beta cell susceptibility for palmitate in vivo. Beta cells and alpha-enriched cell preparations were obtained
from: a-b) Zucker fatty (fa/fa) and lean control rats (fa/-) and exposed for 8 days to 250 mM and 500 mM palmitate or oleate in the presence or
absence of 10 mM TO1317640 nM t10,c12 CLA. Percentages of cytotoxicity are shown as mean6sd, n=3, * p,0.001 fa/fa versus lean control, $
p,0.001 versus palmitate; or isolated from c-d) Wistar rats treated by oral gavages for 5 days with 40mg/kg BW TO1317 or vehicle (DMSO/PBS, 1/3),
and exposed for 2 days to 500 mM palmitate or oleate in the presence or absence of 1 mM TO1317 or 250 mM clofibrate +2 mM 9-cis RA. Results are
shown as mean6sd, n=3, * p,0.001 TO1317-cells versus vehicle, $ p,0.001 versus control; or e-f) Beta cells were FACS sorted based on their
glucose-induced increase in [NAD(P)H]-autofluorescence into two subpopulations characterized by a high or low glucose-responsive phenotype [8],
and exposed for 8 days to 250 mM palmitate or oleate in the presence or absence of 1 mM TO1317 or 250 mM clofibrate plus 2 mM 9-cis RA.
Percentages of cytotoxicity are shown as mean6sd, n=3, * p,0.01 low versus high NAD(P)H-cells; $ p,0.01 agonist treatment versus control. a,c,e)
Q-PCR analysis showing the differences in expression levels of glucokinase, SCD1, SCD2, LXRa, LXRb, PPARa and SREBP1c. Results are shown as
mean6sd, n=3-7, * p,0.05, ** p,0.01 versus the respective control preparations.
doi:10.1371/journal.pone.0007266.g006
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[38,39], but only a limited number of reports has characterized the
role of LXRs in this context [25,26]. LXR activation has been
shown to stimulate insulin secretion in vitro via de novo lipid
synthesis [26,29,40], while in vivo LXR agonists are shown to
reduce serum glucose levels and to improve glucose tolerance and
insulin resistance in obesity models [41,42].
We have used primary beta cell preparations to examine ways
to induce protection against beta cell death during prolonged
exposure (up to 16 days) to elevated concentrations of the
saturated fatty acid palmitate. Protection was seen with PPARa
agonists and correlated with an increased oxidation rate and an
increased expression of genes involved in b-oxidation [7], as well
as in D9-desaturation and lipogenesis. In view of the prior reported
protective action of SCD [19-21], which is mainly a LXR target
gene, we now demonstrate that both PPARa and LXR-agonists
provide long-term protection in rodent and human beta cells
through a pathway involving D9-desaturation. We propose the
following model (schematic overview in Figure 7): D9-desaturase
expression in beta cells is regulated by LXR. Direct activation of
LXR, or induction of LXR downstream of PPARa regulates
SCD-transcription, possibly in a SREBP1c-dependent way. As a
result exogenous palmitate is desaturated, elongated and more
efficiently channeled to neutral storage pools associated with
detoxification. This view is supported by the observation that
TO1317 confers protection to saturated, but not to monounsat-
urated FA; and by the increased toxicity of palmitate upon SCD
inhibition, or by its silencing. SREBP1c, known to regulate
ELOvl6 (which preferentially elongates C16.C18), as well as
SCD-expression [29,43,44], GPAT and DGAT2, both involved in
triglyceride formation, were all induced in response to both LXR
and PPARa ligands, consistent with an accumulation of palmitate
into intracellular lipid pools [29,43,45]. Our observations
unambiguously indicate the involvement of SCD in this process
but do not exclude that protection against palmitate could lay at a
step between fatty acid desaturation and incorporation of
unsaturated fatty acids into neutral lipids. Deposition into neutral
lipids was not essential to induce SCD-protection in Min6 cells
[20]. Newly formed monounsaturated FA could exert specific
protective effects [46].
Absence of LXR abolished protection to palmitate by TO1317,
as well as by clofibrate/9-cis RA. This observation indicates that
PPARa modulates LXR-expression in beta cells, as already shown
for other cell types [47]. PPARa agonists were indeed found to
induce LXRa mRNA levels. These findings further imply that
PPARa-induced protection to saturated FFA largely depends on
LXR-regulated SCD and not on its stimulatory action on fatty
acid oxidation. In contrast to LXR, ligands for PPARa however
not only detoxify saturated [48], but also monounsaturated FFA
[7], indicating that an increased oxidation rate contributes to gain
protection. Islets from mice lacking LXRb showed a strong
suppression of SCD and SREBP1c correlating with an increased
susceptibility to palmitate, but not oleate, which further empha-
sizes the importance of D9-desaturation.
Although the expression levels of LXRa seem to correlate with
resistance to cytotoxicity, our results using LXR knock-out mice
imply that both LXRa and LXRb are required to gain protection
by LXR or PPAR ligands, whereas LXRb seems to control basal
transcription from the SCD-promoter via SREBP1c. These results
point to a complex regulation of the SCD promoter in response to
LXRs, PPARs and SREBP1c. Comparable observations, where
both LXR subtypes are required to control transcription in
concert with PPAR and/or SREBP1c, have been reported for
Elovl5, D6-desaturase and SREBP-1c [33,49].
In the proposed model SREBP1c seems to play a central role
downstream from PPARa and LXR. SREBP1c activation has
already been implicated in the adaptive changes that underlie beta
cell hypersecretion in response to elevated glucose [26,29,50]. In
contrast however, hyper-activation of SREBP1c by its over
expression or its activation by glucose and/or palmitate, has been
Figure 7. Hypothetical lipoprotection model using LXR or PPAR ligands. Long chain saturated FA, such as palmitate, induce cell death
through reactive intermediates, ceramide generation or via ER stress. Activation of LXR downstream of PPARa activates SREBP1c and induces
transcription of genes encoding SCD1 and SCD2. This results in an increased formation of monounsaturated FA and directs the flow of palmitate
towards intracellular storage as neutral lipids. Next to inducing SCD levels, activation of PPARa results in an increased turn-over of FA by stimulation
of b-oxidation, with detoxifying effects on both saturated and monounsaturated FA.
doi:10.1371/journal.pone.0007266.g007
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insulin secretion (GSIS), and was proposed as a mechanism to
explain islet failure in Zucker Diabetic fatty rats (ZDF) [51-56].
Inactivation of SREBP1c in these islets, however, failed to
normalize GSIS, thereby excluding SREBP1 and triglyceride-
accumulation as the main cause behind defective secretion in this
model [57]. Consistent with a role for SREBP1c in controlling
insulin secretion, TO1317 has been shown to stimulate GSIS and
insulin biosynthesis in beta cell lines and mouse islets via a
stimulation of glucose and lipid metabolism [26,29]. Negative
effects of TO1317 on cellular vitality and/or beta cell proliferation
were however also reported and need attention when LXR
agonists would be considered to treat type 2 diabetes [45,58,59].
We therefore examined TO13176palmitate for a period up to 16
days; no adverse effects on cell viability and cell numbers were
observed, and palmitate toxicity was suppressed by an average of
88% during the whole period. In this context it also needs to be
mentioned that TO1317 was recently found, in parallel to SCD1,
to induce CPT1 mRNA levels and to stimulate b-oxidation in
INS1-cells [29], and in hepatocytes [60], whereas TO1317 showed
the opposite effects in our experiments using primary rat beta cells.
These divergent results could relate to differences in experimental
protocols such as FFA concentrations, FFA/BSA ratio’s, use of
serum, or relate to differences in levels and duration of LXR-
activation, but also point to differences between beta cell lines and
primary cells. Lai et al. [61] recently postulated that the lower
sensitivity of human beta cells and Min6 cells to palmitate toxicity
as compared to INS-I cells, could be related to higher SCD1 levels.
In our experiments however, comparable cytotoxic responses to
palmitate (250 and 500 mM) were found for FACS-purified rat,
mouse and human beta cells. Comparison of the expression
profiles of primary cells and cell lines in response to FA and
agonists might reveal differences explaining these divergent
observations. Cross talk between PPAR- and LXR-levels and
competition to bind RXRs or with other nuclear receptors could
play a role [62].
Busch et al. reported that palmitate-resistant Min6 cells were
mainly characterized by an increase of SCD1 [20]. Our study
cannot discriminate between the respective contribution of SCD1
or SCD2. Whereas SCD2 was more prevalent in freshly isolated
beta cells, SCD1 was induced more potently by LXR and PPARa.
SCD1 contains SREBP1c and LXR-responsive elements in its
promoter region, whereas its expression is actively repressed by
leptin [63,64]. Activation of SCD in animals lacking normal leptin
signaling can thus be predicted to lower the cellular susceptibility
to toxic palmitate concentrations. This hypothesis is supported by
our observations on beta cells isolated from TO1317-treated
animals and from Zucker fatty rats (lacking a functional leptin
receptor), which were protected from palmitate but not oleate
toxicity, and by a rise of palmitate toxicity in the presence of an
SCD-inhibitor. The importance of SCD in beta cells is also
documented by the loss of SCD1 in leptin
ob/ob mice, leading to an
accelerated progression to overt diabetes [65]. Absence of SCD in
this model was accompanied by appearance of a morphologically
distinct class of dysfunctional islets showing a suppression of
PPARa and its target genes, increased triglycerides, FFA, and
higher levels of saturated FA than a second class of islets displaying
normal features [65]. These observations are also interesting in
view of the differences in palmitate susceptibility and SCD1
expression levels observed in the high and low glucose-responsive
beta cells, and in view of our prior work where it was shown that
primary beta cells show differences in susceptibility or can even be
resistant to palmitate toxicity [7]. Recent observations in leptin
receptor-overexpressing obese db/db mice showed suppressed
SREBP1c and adipogenic gene-expression levels, severe diabetes
and beta cell loss 6 weeks before the db/db controls [66]. These
findings support the idea that the inherent adipogenic phenotype
of individual beta cells via chain elongation and desaturation
provides the cells with a protective mechanism to cope with
elevated FFA. Our observations contain an important message
since SCD1-inhibitors are evaluated to treat obesity and the
related metabolic syndrome [67,68]. Although suppression of
SCD1 might show beneficial effects on adiposity, these benefits
may come at the expense of pancreatic beta cells. Clinical studies
already indicated an increased risk to develop diabetes in
predisposed obese patients using a mixture of c9,t11 and t10,c12
CLA for weight management [69,70].
In conclusion, activation by PPAR and LXR agonists of a
pathway controlled by LXR involving D9-desaturation, and chain
elongation followed by esterification leads to detoxification of
saturated FA and prevents beta cell death.
Methods
Materials
Chemicals and FA were purchased from Sigma-Aldrich
(Bornem, Belgium). Stock solutions of FA were prepared in 90%
ethanol. Stock solutions of clofibrate, TO1317, PCN and 9-cis RA
were dissolved in absolute ethanol or DMSO. [U-
14C]-palmitic
acid was obtained from Perkin Elmer Life Sciences (Zaventem,
Belgium).
Ethics statement
Animal experiments were approved by the local Ethical
Committee for Animal Experimentation of the Vrije Universiteit
Brussel. All manipulations were carried out in accordance with the
European Community Council Directive (86/609/EEC). Human
endocrine cells were obtained from the Brussels-Beta Cell Bank.
Human pancreata from donors at European hospitals affiliated
with Eurotransplant Foundation (Leiden, The Netherlands) are
processed by the Beta-Cell Bank of the Juvenile Diabetes Research
Foundation Center for Beta Cell Therapy in Brussels with the
purpose of preparing islet cell grafts for clinical trials. Isolated
fractions that do not fulfill the quality criteria for transplantation,
can be made available to research projects approved by the
Medical Ethics Committee of the University Hospital (UZ Brussel-
Vrije Universiteit Brussel). Approval to use beta cells for this
project was obtained from the Medical Ethics Committee of the
UZ Brussels – Vrije Universiteit Brussel.
Isolation and culture of beta cell preparations
Pancreatic islets were isolated from 10 wks old male Wistar and
Zucker rats (lean and fa/fa) and male LXR knock-out mice (8 to 12
wks),. LXRaa
–/–, LXRb
–/–, and LXRaab
–/– mice were back-
crossed from a 129/Sv to a C57BL/6 background for at least ten
generations [71]. Rat and mouse islets were dissociated into single
cells and purified by FACS into beta cells (mean purity 90% insulin-
positive cells) and alpha enriched-cells (75% glucagon-positive cells,
25% insulin-positive cells) using cellular light-scatter and FAD-
autofluorescence as discriminating parameters. The methods for
rodent isletisolation,dissociationandFACSpurificationofisletbeta
and alpha cells have been described previously [72]. In one set of
experiments, rat beta cell subpopulations with, respectively, high
and low glucose-responsiveness were FACS sorted using glucose-
induced increases in cellular level of NAD(P)H-autofluorescence as
discriminator, as described in our previous studies reporting on the
identityandfunctionofthesecells [8,10,37].Humanendocrinecells
were obtained from the Brussels-Beta Cell Bank and prepared as
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were enriched by FACS to a mean purity of 60% beta cells and
furtherenriched under culture conditionsfavoring beta cell survival.
For cell viability experiments, beta cells were cultured in
polylysin-coated microtiter plates with Ham’s F10 containing 10
mM glucose, 1% charcoal-extracted BSA (fraction V, radioim-
munoassay grade, Boerhinger-Mannheim), 2 mM L-glutamine, 50
mM 3-isobutyl-1-methyl-xanthine, 0.075 mg/ml penicillin and 0.1
mg/ml streptomycin. Test reagents were added, with controls
receiving similar dilutions of solvent. The unbound FFA
concentrations in the presence of 1% albumin were calculated to
correspond to 9 and 27 nM after addition of 250 and 500 mM
palmitate using a multiple stepwise equilibrium model using the
association constants for binding of palmitate to the first six
binding sites of albumin, as described by Richieri et al. [74].
Media were refreshed every 2 to 3 days. The percent living and
dead cells was determined as previously described and toxicity
indices calculated [6]. For metabolic and gene expression studies,
freshly isolated cells were re-aggregated and cultured in suspension
[72].
Samples for electron microscopy were fixed in cacodylate-
buffered glutaraldehyde (4.5%, pH 7.3), postfixed in osmium
tetroxide (1%) and embedded in Spurr’s resin. Ultrathin sections
were stained with uranylacetate and lead citrate and examined on
a Zeiss EM 109 electron microscope. Nile red (Molecular probes,
Invitrogen) was used to detect lipid accumulation in living cells
(axioplan, Zeiss).
Palmitate oxidation was measured in KRBH medium contain-
ing 0.2% BSA, 2 mM Ca
2+, 10 mM hepes and 0.5 mCi [U-
14C]-
palmitic acid, and 250 mM unlabeled palmitic acid, as described
prior [7]. The rate of [U-
14C]-palmitic acid oxidation was assessed
through formation of
14CO2 [75].
LXR Agonist Treatment
Male Wistar rats (approx. 250 g), were treated with 40 mg/kg
body weight/day of LXR agonist TO1317 (Sigma–Aldrich)
dissolved in DMSO/PBS (1:3), given daily at the onset of the
dark cycle by oral gavages for 5 days. Control rats were given only
vehicle. After 5 days beta cells and alpha-enriched cells were
FACS-purified and used for viability assays as described.
siRNA Transfection
Transfection was conducted in freshly isolated rat beta cells.
Cells were aggregated in presence of 50 nM siRNA-lipid
complexes using Jetsi-ENDO (Polyplus, France) as transfection
agent [76]. siRNA’s for rat SCD1 and SCD2 were siGENOME
SMART pool reagents (J-096598-00 and L-099222-01; Dharma-
con), pools of four different siRNAs. Control cells were treated
with Jetsi-ENDO only or transfected with non-targeting siGLO
RISC-free (D-001600-01). Transfection did not result in cytotox-
icity. After 24 h, aggregates were dissociated to single cells. Half of
the cells were used in the toxicity assay with an additional 72 h
culture; the other half was reaggregated and RNA extracted 24 h
later. Over 95% of reaggregated siGLO-transfected beta cells
showed cytoplasmic siRNA-associated fluorescence.
Gene, protein and lipid analysis of beta cell aggregates
RNA was extracted using RNeasy columns (Qiagen). RNA
quality was verified by Agilent Bioanalyzer. Following removal of
genomic DNA (TURBO DNA-free, Ambion, Austin, Texas,
U.S.A.) and reverse-transcription (High-Capacity cDNA Archive
Kit, Applied Biosystems, Foster City, U.S.A.), targets were
amplified on ABI Prism 7700 using TaqMan Universal PCR
Master Mix and specific TaqMan MGB probes (Applied
Biosystems, assays’ IDs available on request). Expression levels of
target genes were normalized to b-actin or 18S (DCt) and
expressed versus a chosen calibrator (comparative DDCt method).
Beta cell aggregates were lysed in RIPA buffer containing
protease inhibitors (Sigma). Proteins were resolved by SDS-PAGE
on 10% (w/v) acrylamide:bisacrylamide gels and transferred to
nitrocellulose membranes using iblot (Invitrogen, Belgium).
Immunodetection of SCD was performed using mouse anti-
SCD1/2 antibodies (Abcam). Hsp70 served as housekeeping
control (Santa Cruz Biotechnology, CA, USA). Horseradish
peroxidase-linked secondary antibodies (Santa Cruz Biotechnolo-
gy) were used. Immunoreactive proteins were visualized by
enhanced chemiluminescence (ECL, Pierce).
Lipid extracts were prepared from beta cell aggregates, fortified
with 10 nmol tricosanoic acid (IS), dried and treated with 0.5 ml
0.5 N HCl in 90% acetonitrile at 100uC for 1 hr [77]. After adding
water, released FA were extracted in 2x1 ml hexane, and an
aliquot of the aqueous phase was analyzed for phosphate to
estimate phospholipid content. The hexane extract was dried,
silylated with N-tert butyldimethylsilyl-N-methyltrifluoroaceta-
mide with 1% tert butyldimethylchlorosilane (Pierce)/pyridine
(1/1, v/v) and analyzed by GC-MS (Trace GC-MS, Thermo
Finnigan), equipped with an automated cold-on-column injector
and high oven temperature device connected to a BPX70 column
(30m60.25 mm; 0.25 mm). Fatty acids were identified by
comparing elution times to standards and by their mass spectrum.
Total ion current signals, obtained in EI
+ mode at 35 eV, were
related to the IS signal and converted to nmol fatty acid using
relative response factors by analyzing a reference fatty acid
mixture containing tricosanoic acid (GLC-538, free acids; Nu-
Chek Prep), derivatized like the extracts.
Data analysis
Data are presented as means6SD of n independent experi-
ments. Single comparisons were performed by the Student’s paired
t-test. For multiple comparisons, data were analyzed by ANOVA,
and group comparisons using Student’s paired or unpaired t test,
with correction of the P values for multiple comparisons by the
Bonferroni method.
Supporting Information
Figure S1 Effect of inhibition of SCD on GC-MS fatty acid
profiles. Beta cells were exposed for 8 days to 250 mM-P61 mM
TO13176t10,c12 CLA (40 mM). Lipid extracts were prepared
and analyzed by GC-MS as described. a) Representative
chromatograms, covering the elution of C14:0 till C22:6 Figure
representative for 6 independent analyses. b) The ratios between
the saturated and monounsaturated FA were calculated.
Mean6SE, n=5 - 6, * p,0.05, ** p,0.01 versus control, $
p,0.05, $$,P 0.01 versus palmitate
Found at: doi:10.1371/journal.pone.0007266.s001 (1.47 MB TIF)
Table S1 Effect of TO1317 on cytotoxicity of FA with different
chain length and saturation. Beta cells were exposed for 2 or 8
days to the indicated FA61 mM TO1317. Mean6SD (n.4), #
P,0.001 toxicity of different FA compared to C16:0; * P,0.05,
*** P,0.001, the TO1317 condition compared to the respective
control FA condition.
Found at: doi:10.1371/journal.pone.0007266.s002 (0.04 MB
DOC)
Table S2 mRNA expression levels in islets from LXR KO mice
relative to wild type. qPCR values normalized against 18S and
compared relative to the expression levels in wild type islets.
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were considered significant with p,0.01. ** p,0.01 and ***
p,0.001, compared to wild type control. ND=not detected
Found at: doi:10.1371/journal.pone.0007266.s003 (0.05 MB
DOC)
Table S3 mRNA expression levels in beta cells from Zucker
obese rats relative to lean controls. qPCR values normalized
against b-actin and expressed relative to the expression levels in
beta cells from Zucker lean controls. Unpaired student t-test, two
tailed, mean6SD, n=3, Differences were considered significant
with ** p,0.01 and *** p,0.001.
Found at: doi:10.1371/journal.pone.0007266.s004 (0.05 MB
DOC)
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